Moreover, we explored the efficacy of KTC1101 in combination with anti-PD-1 immunotherapy, applying an intermittent dosing schedule aimed at maximizing anti-tumor effects while minimizing adverse side effects. The gene discussed is PDCD1; the disease is neoplasm.